Collaborations

Partnership signed to develop vaccine for hepatitis C

Published in Hepatitis Weekly, February 6th, 2006

Inovio Biomedical Corp. (INO), a late stage developer of cancer and other therapies using electroporation to deliver drugs and nucleic acids, has signed an agreement with Swedish-based Tripep AB (TPEP) to develop a therapeutic vaccine for hepatitis C virus (HCV).

The vaccine will be based on Tripep's proprietary HCV antigen and delivered to infected individuals using Inovio's Medpulser DNA Delivery System. Initiation of a phase I clinical trial is expected to begin in 2006 and will be performed in Sweden.

Hepatitis C virus is a major cause of chronic liver disease worldwide. The standard treatment for HCV, combination therapy with pegylated...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2006-02-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry